Heart Failure Clinical Trial
Official title:
An Open Label, Descriptive Study to Evaluate the Clinical Utility of a Novel Formulation of Furosemide Delivered Subcutaneously in Patients Presenting With Early Signs of Fluid Overload
Verified date | August 2021 |
Source | Steward St. Elizabeth's Medical Center of Boston, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the usefulness of the subcutaneous administration of a new Lasix formulation. 20 patients will be evaluated in the first phase (pilot phase) and depending on the results, an additional 40 patients will be enrolled (Evaluation Phase). Patients with mild to moderate evidence of fluid overload who present to the cardiology service at St Elizabeth's Medical Center, Brighton, Massachusetts (SEMC) will be included in the study. Patients who qualify for thus study will be sent home with the sc2Wear™ Furosemide Infusor therapy for three days. This is a pump that patients place on their abdomen and it then delivers furosemide to the skin. Participants will be visited at home by a visiting nurse who will give them further teaching on the sc2Wear™ Furosemide Infusor. The visiting nurse will also be responsible for obtaining history (symptoms), physical examination (including inspecting the skin for adverse reactions related to the pump), and laboratory draws, supplementation of electrolytes as needed. Patients will be evaluated by the cardiology service of SEMC within 24 hours of the last dose of the sc2Wear™ Furosemide Infusor. If a patient is found to have satisfactorily responded but requires more therapy, an additional 4 days may be prescribed for total of seven consecutive treatments. If additional units are prescribed, patients will be evaluated by the cardiology service of SEMC within 24 hours of the last dose of the sc2Wear™ Furosemide infusion. Also an additionally, up to three-sc2Wear furosemide at home treatments may be used as authorized by the treating physician in case the patient experiences worsening heart failure within 30-days of enrollment (Rescue Treatment). Participants will be seen in clinic for follow up at 30±3 days after the start of the study for a post treatment.
Status | Terminated |
Enrollment | 9 |
Est. completion date | January 31, 2019 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age= 18 years - Symptomatic and chronic heart failure (NYHA Class II and III). - Patients on guideline directed medical therapy 90 days prior to enrollment. - Adequate home environment for at-home treatment. - Presenting or referred to the clinic because of evidence of worsening heart failure with fluid overload (decompensation). - A modification in oral diuretics is not clinically appropriate as deemed by the investigator. - Estimated excess fluid weight of 4 lbs. or more from euvolemic state. - Participant able to give informed consent for participation in trial. Agreeing to sign informed consent and HIPAA authorization. - Understanding and willing to comply with the protocols of the trial. - Ability of the participant or caregiver to independently apply the investigational device and medication Exclusion Criteria: - ACC/AHA Stage D heart failure or patients requiring IV inotrope therapy. - Massive volume overload (e.g. >20 lbs. of estimated fluid weight) or anasarca. - Suspected high risk clinical instability with outpatient treatment. - Pregnant females or women of child-bearing age who are not willing to use an adequate form of contraception. - Chronic Obstructive Pulmonary Disease (COPD) moderate or worse: FEV1/FCV ratio <0.7 and FEV1 <60 percent predicted. - Rapid atrial fibrillation (AF) (HR >100b/min) - Hypoxia (resting O2 saturation <90%). - Hypotension (systolic blood pressure (SBP) BP < 90 mmHg). - Uncontrolled diabetes mellitus (DM) (admission glucose levels > 300 mg/dL). - Advanced renal disease (eGFR < 30mL/min/1.73m2). - Acute coronary syndrome. - Serum potassium (K) <3.2 mmol/L or > 5.5mmol/L. - On experimental medication or currently participating in an interventional cardiovascular research study, other than an observational or registry study. - Having received intravenous furosemide within 24 hours prior to enrollment. - Urinary tract abnormality or disorder interfering with urination. - Allergy to the active and inactive ingredients of the study medication. - Inability to comply with study requirements. - Ongoing substance abuse. - Concern that the current episode of decompensation was precipitated by a serious medical condition which may require additional evaluation or treatment. - Dementia |
Country | Name | City | State |
---|---|---|---|
United States | St ELizabeth's Medical Center | Brighton | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Steward St. Elizabeth's Medical Center of Boston, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight Change | Weight change between enrollment/screening compared to last observation | 30 days | |
Primary | Pro BNP Change | Reduction in pro-BNP between enrollment/screening compared to last observation | 30 days | |
Primary | Survival | % of patients alive 30 days post enrollment | 30 days | |
Primary | Hospital Admission for Heart Failure | % of patients without hospitalization for worsening HF within 30 days after enrollment | 30 days | |
Primary | Heart Failure Related Events | % of patients without a significant Heart Failure related medical events within 30 days after enrollment. | 30 days | |
Primary | Extra Furosemide Treatment | Percentage of patients requiring additional 4 days of diuresis | 7 days | |
Primary | Number of Participants That Discontinued Due to Presence of Skin Reaction to Drug or Device/Adhesive | The number of participants that discontinued study participation due to the presence of a skin reaction to the drug or device/adhesive. | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|